EUVIMEDEUVIMED entdecken
Crossref

Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)

Maeve A Hennessy, Jeffrey P Leal, Chiung-Yu Huang, Lilja B Solnes, Rita Denbow, Vandana G Abramson, Lisa A Carey, Minetta C Liu, Mothaffar Rimawi, Jennifer Specht, Anna Maria Storniolo, Vicente Valero und 8 weitere

Journal of Nuclear Medicine · 2023

DOI: 10.2967/jnumed.123.265853 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Maeve A Hennessy und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research @UCC, Cork, Ireland; roisin.connolly@ucc.ie 122108045@umail.ucc.ie. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Predictive biomarkers of response to human epidermal growth factor receptor 2 (HER2)-directed therapy are essential to inform treatment decisions. The TBCRC026 trial reported that early declines in tumor SUVs corrected for lean body mass (SULmax) on 18F-FDG PET/CT predicted a pathologic complete response (pCR) to HER2 therapy with neoadjuvant trastuzumab and pertuzumab (HP) without chemotherapy in estrogen receptor (ER)-negative, HER2-positive breast cancer. We hypothesized that 18F-FDG PET/CT SULmax parameters would predict recurrence-free survival (RFS) and overall survival (OS).

Methods

Patients with stage II/III ER-negative, HER2-positive breast cancer received neoadjuvant HP (n = 88). pCR after HP alone was 22% (18/83), additional nonstudy neoadjuvant therapy was administered in 28% (25/88), and the majority received adjuvant therapy per physician discretion. 18F-FDG PET/CT was performed at baseline and at cycle 1, day 15 (C1D15). RFS and OS were summarized using the Kaplan-Meier method and compared between subgroups using logrank tests. Associations between 18F-FDG PET/CT (≥40% decline in SULmax between baseline and C1D15, or C1D15 SULmax ≤ 3) and pCR were evaluated using Cox regressions, where likelihood ratio CIs were reported because of the small numbers of events.

Results

Median follow-up was 53.7 mo (83/88 evaluable), with 6 deaths and 14 RFS events. Estimated RFS and OS at 3 y was 84% (95% CI, 76%-92%) and 92% (95% CI, 87%-98%), respectively. A C1D15 SULmax of 3 or less was associated with improved RFS (hazard ratio [HR], 0.36; 95% CI, 0.11-1.05; P = 0.06) and OS (HR, 0.14; 95% CI, 0.01-0.85; P = 0.03), the latter statistically significant. The association of an SULmax decline of at least 40% (achieved in 59%) with RFS and OS did not reach statistical significance. pCR was associated with improved RFS (HR, 0.25; 95% CI, 0.01-1.24; P = 0.10) but did not reach statistical significance.

Conclusion

For the first time, we report a potential association between a C1D15 SULmax of 3 or less on 18F-FDG PET/CT and RFS and OS outcomes in patients with ER-negative, HER2-positive breast cancer receiving neoadjuvant HP alone. If confirmed in future studies, this imaging-based biomarker may facilitate early individualization of therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyTreatment OutcomeErb-b2 Receptor Tyrosine KinasesTrastuzumabPositron-Emission TomographyNeoadjuvant TherapyAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

FDG PET/CTHER2-positivebiomarkersbreast cancerneoadjuvant

Substanzen

Fluorodeoxyglucose F18Erb-b2 Receptor Tyrosine KinasesTrastuzumab

Autor:innen und Institutionen

  • Cancer Research @UCC, Cork, Ireland; roisin.connolly@ucc.ie 122108045@umail.ucc.ie.
  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, Maryland.
  • University of California, San Francisco, California.
  • Vanderbilt University, Nashville, Tennessee.
  • University of North Carolina, Chapel Hill, North Carolina.
  • Mayo Clinic, Rochester, Minnesota.

Zitieren

APA

Hennessy, M. A., Leal, J. P., Huang, C. Y., Solnes, L. B., Denbow, R., Abramson, V. G., Carey, L. A., Liu, M. C., Rimawi, M., Specht, J., Storniolo, A. M., Valero, V., Vaklavas, C., Winer, E. P., Krop, I. E., Wolff, A. C., Cimino-Mathews, A., Wahl, R. L., Stearns, V., & Connolly, R. M. (2023). Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.265853

Vancouver

Hennessy MA, Leal JP, Huang CY, Solnes LB, Denbow R, Abramson VG, et al. Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.265853

BibTeX
@article{Hennessy2023,
  author = {Hennessy, Maeve A and Leal, Jeffrey P and Huang, Chiung-Yu and Solnes, Lilja B and Denbow, Rita and Abramson, Vandana G and Carey, Lisa A and Liu, Minetta C and Rimawi, Mothaffar and Specht, Jennifer and Storniolo, Anna Maria and Valero, Vicente and Vaklavas, Christos and Winer, Eric P and Krop, Ian E and Wolff, Antonio C and Cimino-Mathews, Ashley and Wahl, Richard L and Stearns, Vered and Connolly, Roisin M},
  title = {Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  doi = {10.2967/jnumed.123.265853}
}
Kostenlos starten →